Waltham, MA, United States of America

Ryan Lim

This inventor holds 1 USPTO granted patent. Top assignee: Symbiotic Capital Agency LLC, as Administrative and Collateral Agent. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ryan Lim: Innovator in Glycosyltransferase Enzyme Technology

Introduction

Ryan Lim is an accomplished inventor based in Waltham, MA (US). He has made significant contributions to the field of biochemistry, particularly through his work on glycosyltransferase enzymes. His innovative approach has led to the development of a unique patent that showcases his expertise and dedication to advancing scientific knowledge.

Latest Patents

Ryan Lim holds a patent for the invention titled "Uridine Diphosphate-Dependent Glycosyltransferase Enzyme." This patent represents a significant advancement in the understanding and application of glycosyltransferase enzymes, which play a crucial role in various biological processes.

Career Highlights

Currently, Ryan Lim works at Symbiotic Capital Agency LLC as an Administrative and Collateral Agent. His role involves managing various administrative tasks and ensuring the smooth operation of the agency. His experience in this position complements his inventive work, allowing him to apply his scientific knowledge in a practical business context.

Collaborations

Ryan collaborates with talented individuals such as Jason Donald and Ajikumar Parayil Kumaran. These partnerships enhance his innovative efforts and contribute to the overall success of his projects.

Conclusion

Ryan Lim is a notable inventor whose work in glycosyltransferase enzyme technology has the potential to impact various scientific fields. His dedication to innovation and collaboration underscores his commitment to advancing biochemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…